First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025)